Journal of affective disorders · 2026
Comparative risk of early-onset dementia with lithium versus valproate in bipolar disorder: A real-world cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Chi-Syuan, Jung Chau-Ren, Yu Shao-Hua, Wang Wei-Chun, Wu Shih-Hao, Huang Fen-Wei, Tsai Tsung-Lin
Аннотация
BACKGROUND: Bipolar disorder is associated with an elevated risk of dementia. While lithium may exert neuroprotective effects, its comparative impact on early-onset dementia versus valproate, a mood stabilizer with potential neurotoxicity remains unclear in younger populations. This study aimed to compare the risk of early-onset dementia between patients with bipolar disorder initiating lithium versus valproate therapy.
METHODS: This retrospective, active-comparator, new-user cohort study using the TriNetX global health research network. The study period was from January 1, 2015, to December 31, 2024. We identified patients aged 18-60 years newly diagnosed with bipolar disorder who initiated either lithium or valproate. Patients with prevalent dementia were excluded. Propensity score matching (1:1) was used to balance baseline characteristics including comorbidities and renal function. The primary outcome was incident dementia within 5 years of the index date. Hazard ratios (HRs) were estimated using Cox proportional hazards models.
RESULTS: The matched cohort included 82,172 patients (41,086 per group; mean age 37.4 years; 54.4% female). Over the 5-year follow-up, lithium initiation was associated with a lower risk of dementia compared with valproate (HR 0.815, 95% CI 0.717-0.926; p = 0.002). This comparative association remained consistent across extended 10-year follow-up, complete-case, and all-cause mortality sensitivity analyses.
LIMITATIONS: Observational design precludes causal inference; lack of granular dosage data prevents dose-response analysis.
CONCLUSIONS: Lithium is associated with a lower risk of early-onset dementia compared to valproate.
METHODS: This retrospective, active-comparator, new-user cohort study using the TriNetX global health research network. The study period was from January 1, 2015, to December 31, 2024. We identified patients aged 18-60 years newly diagnosed with bipolar disorder who initiated either lithium or valproate. Patients with prevalent dementia were excluded. Propensity score matching (1:1) was used to balance baseline characteristics including comorbidities and renal function. The primary outcome was incident dementia within 5 years of the index date. Hazard ratios (HRs) were estimated using Cox proportional hazards models.
RESULTS: The matched cohort included 82,172 patients (41,086 per group; mean age 37.4 years; 54.4% female). Over the 5-year follow-up, lithium initiation was associated with a lower risk of dementia compared with valproate (HR 0.815, 95% CI 0.717-0.926; p = 0.002). This comparative association remained consistent across extended 10-year follow-up, complete-case, and all-cause mortality sensitivity analyses.
LIMITATIONS: Observational design precludes causal inference; lack of granular dosage data prevents dose-response analysis.
CONCLUSIONS: Lithium is associated with a lower risk of early-onset dementia compared to valproate.